Daintree Core Income Fund (ECOR)
CXA 
Summary
RBC reiterates 'outperform' on Ecora Royalties after Voisey's Bay site visit boosts confidence
RBC Capital Markets has reiterated its 'outperform' rating and 185p price target on Ecora Royalties PLC (LSE:ECOR, TSX:ECOR, OTCQX:ECRAF, FRA:HGR) after a site visit to the Voisey's Bay cobalt and copper mine in Newfoundland and Labrador left the bank with materially greater confidence in the asset's operational delivery and growth potential. The note, from analysts Ben Davis, Laura Chan and Marina Calero, describes a step-change in execution at Voisey's Bay, where the transition to underground mining is now largely complete with throughput running at nameplate capacity.
electroCore Touts 30% Growth Outlook, VA Opportunity at LD Micro Conference
electroCore NASDAQ: ECOR Interim President and CFO Joshua Lev said the bioelectronic technology company is focused on expanding its non-invasive vagus nerve stimulation platform across federal health care, commercial insurance channels and consumer wellness markets.
electroCore, Inc. (ECOR) Q1 2026 Earnings Call Transcript
electroCore, Inc. (ECOR) Q1 2026 Earnings Call Transcript
Daintree Core Income Fund (ECOR) FAQ
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Daintree Core Income Fund ever had a stock split?
Daintree Core Income Fund Profile
| CXA Exchange | US Country |
Overview
electroCore, Inc. is a commercial-stage bioelectronic medicine and wellness company focused on the innovation and commercialization of non-invasive vagus nerve stimulation (nVNS) therapies. The company is at the forefront of developing technology-driven solutions for treating pain associated with migraines and episodic cluster headaches in adults, alongside supporting general health and wellbeing, and enhancing human performance. Founded in 2005 and with its headquarters in Rockaway, New Jersey, electroCore is dedicated to improving the quality of life for patients through its groundbreaking products.
Products and Services
- gammaCore
- Truvaga
- TAC-STIM
- gammaCore Sapphire
A prescription-only nVNS therapy device designated for the acute treatment of pain associated with migraine and episodic cluster headache in adults. The electroCore’s innovation, gammaCore, represents a non-invasive approach, leveraging vagus nerve stimulation to provide relief from the debilitating pain caused by migraines and cluster headaches. Its ease of use and non-invasive nature make it a valuable tool for those seeking alternatives to traditional treatment methods.
Developed by electroCore, Truvaga is a nVNS therapy aimed at supporting general health and wellbeing. This product epitomizes the company’s commitment to expanding the application of bioelectronic medicine beyond pain management, introducing a wellness aspect to their portfolio. Truvaga is designed to harness the benefits of vagus nerve stimulation in a manner that promotes overall health, providing an innovative solution for individuals looking to enhance their wellbeing.
A specialized form of nVNS developed for enhancing human performance, TAC-STIM reflects electroCore’s venture into the domain of performance optimization using bioelectronic medicine. This product is tailored for individuals seeking to improve their physical and cognitive performance through non-invasive means, marking an exciting development in the field of human enhancement technologies.
As the lead product in electroCore’s lineup, gammaCore Sapphire is a rechargeable, reloadable handheld device designed for the administration of nVNS therapy over many years. Its user-friendly, durable design ensures that patients can manage their treatment effectively and efficiently, without the need for frequent replacements or disposals. The gammaCore Sapphire stands as a testament to electroCore’s commitment to sustainability and long-term patient care.
